Picture of GSK logo

GSK GSK News Story

0.000.00%
gb flag iconLast trade - 00:00
HealthcareConservativeLarge CapHigh Flyer

REG - GlaxoSmithKline PLC - Director/PDMR Shareholding <Origin Href="QuoteRef">GSK.L</Origin>

RNS Number : 6940T
GlaxoSmithKline PLC
16 October 2017

GlaxoSmithKline plc(the'Company')

Transaction notification

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Ms E Walmsley

b)

Position/status

Chief Executive Officer

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Descriptionofthefinancial instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

b)

Natureofthetransaction

Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 12 October 2017 on Ordinary Shares held in the Company's Deferred Investment Award Programme.

c)

Price(s)and

volume(s)

Price(s)

Volume(s)

15.2425

262.743

d)

Aggregatedinformation

AggregatedvolumePrice

n/a (single transaction)

e)

Date ofthetransaction

2017-10-12

f)

Placeofthe transaction

n/a

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr R G Connor

b)

Position/status

President, Global Manufacturing & Supply

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Descriptionofthefinancial instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

b)

Natureofthetransaction

Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 12 October 2017, on Ordinary Shares held in the Company's Deferred Investment Award Programme.

c)

Price(s)and

volume(s)

Price(s)

Volume(s)

15.2425

105.097

d)

Aggregatedinformation

AggregatedvolumePrice

n/a (single transaction)

e)

Date ofthetransaction

2017-10-12

f)

Placeofthe transaction

n/a

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr B McNamara

b)

Position/status

CEO, GSK Consumer Healthcare

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Descriptionofthefinancial instrument

GlaxoSmithKline plc American Depositary Shares ('ADSs')

ISIN: US37733W1053

b)

Natureofthetransaction

Increase in notional interest in ADSs following the re-investment of dividends paid to shareholders on 12 October 2017 on ADSs held in the Company's Deferred Investment Award Programme.

c)

Price(s)and

volume(s)

Price(s)

Volume(s)

$40.9497

330.748

d)

Aggregatedinformation

AggregatedvolumePrice

n/a (single transaction)

e)

Date ofthetransaction

2017-10-12

f)

Placeofthe transaction

n/a

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr D S Redfern

b)

Position/status

Chief Strategy Officer

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Descriptionofthefinancial instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

b)

Natureofthetransaction

Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 12 October 2017 on Ordinary Shares held in the Company's Deferred Investment Award Programme.

c)

Price(s)and

volume(s)

Price(s)

Volume(s)

15.2425

105.097

d)

Aggregatedinformation

AggregatedvolumePrice

n/a (single transaction)

e)

Date ofthetransaction

2017-10-12

f)

Placeofthe transaction

n/a

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Ms C Thomas

b)

Position/status

Senior Vice President, HR

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Descriptionofthefinancial instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

b)

Natureofthetransaction

Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 12 October 2017 on Ordinary Shares held in the Company's Deferred Investment Award Programme.

c)

Price(s)and

volume(s)

Price(s)

Volume(s)

15.2425

105.097

d)

Aggregatedinformation

AggregatedvolumePrice

n/a (single transaction)

e)

Date ofthetransaction

2017-10-12

f)

Placeofthe transaction

n/a

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Dr P J T Vallance

b)

Position/status

President, R&D

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Descriptionofthefinancial instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

b)

Natureofthetransaction

Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 12 October 2017 on Ordinary Shares held in the Company's Deferred Investment Award Programme.

c)

Price(s)and

volume(s)

Price(s)

Volume(s)

15.2425

131.371

d)

Aggregatedinformation

AggregatedvolumePrice

n/a (single transaction)

e)

Date ofthetransaction

2017-10-12

f)

Placeofthe transaction

n/a


This information is provided by RNS
The company news service from the London Stock Exchange
END
DSHKQLBFDBFEFBQ

Recent news on GSK

See all news